TELA · TELA Bio, Inc.

Summary

TELA Bio, Inc. received a deficiency letter from Nasdaq on March 17, 2026, notifying that its common stock's closing bid price was below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The Company has 180 calendar days until September 14, 2026, to regain compliance by achieving $1.00+ closes for 10 consecutive business days, with no immediate effect on its Nasdaq Global Market listing.

Key takeaways

• Received Nasdaq deficiency letter on March 17, 2026
• Closing bid price below $1.00 for 30 consecutive business days prior to notice
• 180 calendar days to comply, ending September 14, 2026
• Compliance via $1.00+ bid price for 10 consecutive business days
• Possible second 180-day period if transfers to Nasdaq Capital Market
• Stock continues trading on Nasdaq Global Market under symbol TELA